Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

supplySHOCK Jun. 4 at 10:42 AM

$RGNT $ACXP $CTNT $KITT story

0 · Reply

MilsLearning May. 22 at 12:07 PM

$ACXP 🖕🩳🔥

0 · Reply

SuperGreenToday May. 19 at 6:49 PM

$ACXP

0 · Reply

focafoca99 May. 19 at 4:38 PM

$ACXP explains FDA's new CDI guidance that could speed approval for its ibezapolstat antibiotic.

0 · Reply

PUMPLESTILTSKIN May. 15 at 5:21 PM

$ACXP should see under a dollar in a month at current rate of decline. Luci you suck.

1 · Reply

NotBornYesterday May. 15 at 12:54 PM

$ACXP bill now up to 20 co-sponsors. https://www.congress.gov/bill/119th-congress/house-bill/7352/cosponsors?pageSort=lastToFirst&loclr=cga-bill

1 · Reply

EarningsInsider May. 12 at 1:00 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-acurx-pharmaceuticals-inc-stock/ $ACXP Acurx Pharmaceuticals Earnings Transcript

0 · Reply

NotBornYesterday May. 12 at 12:46 PM

$ACXP

0 · Reply

StocktwitsEarnings May. 12 at 10:00 AM

$ACXP Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 up 71.16% YoY • On March 9, 2026, Acurx Pharmaceuticals announced a new clinical development initiative to expand the ibezapolstat program into recurrent C. difficile infection, with enrollment expected in the fourth quarter of this year.

0 · Reply

PUMPLESTILTSKIN May. 8 at 4:05 PM

$ACXP

0 · Reply

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 23 days ago

Acurx Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 23 days ago

Acurx Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 7:01 AM EDT - 23 days ago

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

2026-05-04T20:30:19.000Z - 4 weeks ago

Acurx files to sell 1.65M shares of common stock for holders

2026-05-04T20:29:36.000Z - 4 weeks ago

Acurx files to sell 1.3M shares of common stock for holders

May 4, 2026, 8:00 AM EDT - 4 weeks ago

Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026

May 4, 2026, 8:00 AM EDT - 4 weeks ago

Acurx Pharmaceuticals Registration statement: Registration filing

May 4, 2026, 8:00 AM EDT - 4 weeks ago

Acurx Pharmaceuticals Registration statement: Registration filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit

Apr 20, 2026, 8:00 AM EDT - 6 weeks ago

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

Apr 16, 2026, 4:01 PM EDT - 7 weeks ago

Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2026-04-16T14:19:45.000Z - 7 weeks ago

Acurx announces $7.1M registered direct offering priced at-the-market

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2026-04-07T13:33:21.000Z - 2 months ago

New to The Street announce re-signing of Acurx Pharmaceuticals

2026-03-30T11:05:37.000Z - 2 months ago

Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors

Mar 30, 2026, 7:01 AM EDT - 2 months ago

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

2026-03-13T16:50:20.000Z - 2 months ago

Acurx price target lowered to $10 from $20 at Alliance Global

Mar 13, 2026, 8:00 AM EDT - 2 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 2 months ago

Acurx Pharmaceuticals Earnings release: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 2 months ago

Acurx Pharmaceuticals Annual report: Q4 2025

Mar 13, 2026, 7:01 AM EDT - 2 months ago

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

2026-03-13T00:49:02.000Z - 2 months ago

Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate

2026-03-09T12:05:07.000Z - 3 months ago

Acurx announces new ibezapolstat clinical trial program

Mar 9, 2026, 8:01 AM EDT - 3 months ago

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

Feb 16, 2026, 8:01 AM EST - 3 months ago

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

2026-02-02T21:50:10.000Z - 4 months ago

Acurx files to sell 750,000 shares of common stock for holders

2026-02-02T13:06:26.000Z - 4 months ago

Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO

Feb 2, 2026, 8:00 AM EST - 4 months ago

USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Feb 2, 2026, 7:00 AM EST - 4 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Dec 30, 2025, 7:00 AM EST - 5 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Nov 18, 2025, 8:00 AM EST - 7 months ago

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Nov 12, 2025, 8:00 AM EST - 7 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Acurx Pharmaceuticals Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Acurx Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 7:01 AM EST - 7 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

2025-11-10T13:10:40.000Z - 7 months ago

Acurx announces publication of results from ibezapolstat study

Nov 10, 2025, 8:00 AM EST - 7 months ago

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

2025-10-20T21:30:17.000Z - 8 months ago

Acurx files to sell 585,000 shares of common stock for holders

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing

2025-10-09T11:36:04.000Z - 8 months ago

Acurx granted new patent for DNA Polymerase IIIC Inhibitors

Oct 9, 2025, 7:30 AM EDT - 8 months ago

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

2025-09-30T11:35:07.000Z - 8 months ago

Acurx’s ibezapolstat receives positive EMA opinion in C. difficile infection

Sep 30, 2025, 7:30 AM EDT - 8 months ago

Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

Sep 3, 2025, 7:01 AM EDT - 9 months ago

Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

2025-08-12T13:25:41.000Z - 10 months ago

Acurx target adjusted to $31 from $8 at H.C. Wainwright

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 7:01 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

Aug 4, 2025, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

Jul 31, 2025, 9:25 AM EDT - 11 months ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 24, 2025, 8:00 AM EDT - 11 months ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

Jul 24, 2025, 7:01 AM EDT - 11 months ago

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Jul 15, 2025, 8:00 AM EDT - 11 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Jun 17, 2025, 9:47 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 7:01 AM EDT - 1 year ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 9, 2025, 7:30 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

May 29, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 29, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Registration statement: Registration Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Proxy statement: Proxy Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 17, 2025, 7:30 AM EDT - 1 year ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Earnings release: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 3, 2025, 8:00 AM EST - 1 year ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Feb 28, 2025, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 19, 2025, 8:00 AM EST - 1 year ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Jan 31, 2025, 7:00 AM EST - 1 year ago

Acurx Pharmaceuticals Registration statement: Registration Filing

Jan 7, 2025, 5:00 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 1 year ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 1 year ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 1 year ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 7:01 AM EST - 1 year ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 7:00 AM EST - 1 year ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals Earnings release: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Oct 21, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 14, 2024, 1:00 PM EDT - 1 year ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Oct 11, 2024, 10:50 AM EDT - 1 year ago

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

supplySHOCK Jun. 4 at 10:42 AM

$RGNT $ACXP $CTNT $KITT story

0 · Reply

MilsLearning May. 22 at 12:07 PM

$ACXP 🖕🩳🔥

0 · Reply

SuperGreenToday May. 19 at 6:49 PM

$ACXP

0 · Reply

focafoca99 May. 19 at 4:38 PM

$ACXP explains FDA's new CDI guidance that could speed approval for its ibezapolstat antibiotic.

0 · Reply

PUMPLESTILTSKIN May. 15 at 5:21 PM

$ACXP should see under a dollar in a month at current rate of decline. Luci you suck.

1 · Reply

NotBornYesterday May. 15 at 12:54 PM

$ACXP bill now up to 20 co-sponsors. https://www.congress.gov/bill/119th-congress/house-bill/7352/cosponsors?pageSort=lastToFirst&loclr=cga-bill

1 · Reply

EarningsInsider May. 12 at 1:00 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-acurx-pharmaceuticals-inc-stock/ $ACXP Acurx Pharmaceuticals Earnings Transcript

0 · Reply

NotBornYesterday May. 12 at 12:46 PM

$ACXP

0 · Reply

StocktwitsEarnings May. 12 at 10:00 AM

0 · Reply

PUMPLESTILTSKIN May. 8 at 4:05 PM

$ACXP

0 · Reply

NotBornYesterday May. 1 at 1:37 PM

$ACXP For the last several decades, the country ignored the deterioration of sustaining investments needed for the energy and mining industries. Recognition of those shortfalls has finally occurred and policy is changing. Not dissimilar, antimicrobial resistance has been ignored and is now an acute issue. Recognition and policy change is coming.

0 · Reply

StealthxPro Apr. 30 at 2:33 PM

$ACXP to the moon 🌝

0 · Reply

NotBornYesterday Apr. 30 at 1:00 PM

$ACXP So under what scenario would a former shareholder, who hasn't written the company off yet, decide to re-enter a position?

2 · Reply

Cpictures Apr. 28 at 4:10 PM

$ACXP Friendly reminder that this is not a real company. It is two old men that own patent collecting fat paychecks by diluting a few times a year. There is no lab. There is no research. There is no HQ. They pay two-bit media companies for interviews and press releases every so often to keep up appearances.

0 · Reply

NotBornYesterday Apr. 28 at 12:48 PM

$ACXP BoD should authorize co to hold gold as treasury asset…and mgmt should start DCA’ing into it. Stagflation is here.

0 · Reply

newsfile_corp Apr. 27 at 12:00 PM

https://nfne.ws/294135 $ACXP #Energy #NASDAQ #Investing

0 · Reply

NotBornYesterday Apr. 23 at 5:03 PM

$ACXP Balance sheet is in best shape in 3+ years, cash runway has clear visibility to mid-2027, negative EV discounting doom, 9 figure sunk cost of establishing safety and Proof of Concept is in the past, re-introduction of Pasteur is no longer hope but fact. Meanwhile, the hate is palpable.

1 · Reply

RCInvestor Apr. 23 at 4:15 PM

$ACXP will buy after 10 days from now

2 · Reply

MarketForecasting Apr. 23 at 4:01 PM

$ACXP *before the end of this week Trash bag of a company

0 · Reply

BankingBig Apr. 23 at 2:55 PM

$ACXP lmfao.. I buy this because it appeared to stable around 2.20 lmfao.. then drops another 10% I'm officially done ever touching this POS

0 · Reply

PUMPLESTILTSKIN Apr. 23 at 2:23 PM

$ACXP drop 80 cents and another all time low will be made. will probably take 2 weeks at the current rate. Unless Luci does another pr blitz and fakes out a bunch of newbies.

1 · Reply

BankingBig Apr. 22 at 7:45 PM

$ACXP back in for a small bite here

0 · Reply

Market Cap	7.74M
Revenue (ttm)	0.00
Net Income (ttm)	-7.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	35,400
Avg Vol	182,926
Day's Range	N/A - N/A
Shares Out	4.30M
Stochastic %K	5%
Beta	-2.09
Analysts	Strong Sell
Price Target	$17.00